These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 31884854)

  • 1. Effects of Interleukin-1β Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk: A Secondary Analysis of CANTOS.
    Rothman AM; MacFadyen J; Thuren T; Webb A; Harrison DG; Guzik TJ; Libby P; Glynn RJ; Ridker PM
    Hypertension; 2020 Feb; 75(2):477-482. PubMed ID: 31884854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
    Ridker PM; MacFadyen JG; Thuren T; Everett BM; Libby P; Glynn RJ;
    Lancet; 2017 Oct; 390(10105):1833-1842. PubMed ID: 28855077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Interleukin-1β Inhibition on Incident Anemia: Exploratory Analyses From a Randomized Trial.
    Vallurupalli M; MacFadyen JG; Glynn RJ; Thuren T; Libby P; Berliner N; Ridker PM
    Ann Intern Med; 2020 Apr; 172(8):523-532. PubMed ID: 32203978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes.
    Everett BM; Donath MY; Pradhan AD; Thuren T; Pais P; Nicolau JC; Glynn RJ; Libby P; Ridker PM
    J Am Coll Cardiol; 2018 May; 71(21):2392-2401. PubMed ID: 29544870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.
    Ridker PM; MacFadyen JG; Everett BM; Libby P; Thuren T; Glynn RJ;
    Lancet; 2018 Jan; 391(10118):319-328. PubMed ID: 29146124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease.
    Ridker PM; MacFadyen JG; Glynn RJ; Koenig W; Libby P; Everett BM; Lefkowitz M; Thuren T; Cornel JH
    J Am Coll Cardiol; 2018 May; 71(21):2405-2414. PubMed ID: 29793629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ
    Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial.
    Everett BM; MacFadyen JG; Thuren T; Libby P; Glynn RJ; Ridker PM
    J Am Coll Cardiol; 2020 Oct; 76(14):1660-1670. PubMed ID: 33004131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
    Ridker PM; Everett BM; Thuren T; MacFadyen JG; Chang WH; Ballantyne C; Fonseca F; Nicolau J; Koenig W; Anker SD; Kastelein JJP; Cornel JH; Pais P; Pella D; Genest J; Cifkova R; Lorenzatti A; Forster T; Kobalava Z; Vida-Simiti L; Flather M; Shimokawa H; Ogawa H; Dellborg M; Rossi PRF; Troquay RPT; Libby P; Glynn RJ;
    N Engl J Med; 2017 Sep; 377(12):1119-1131. PubMed ID: 28845751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual inflammatory risk associated with interleukin-18 and interleukin-6 after successful interleukin-1β inhibition with canakinumab: further rationale for the development of targeted anti-cytokine therapies for the treatment of atherothrombosis.
    Ridker PM; MacFadyen JG; Thuren T; Libby P
    Eur Heart J; 2020 Jun; 41(23):2153-2163. PubMed ID: 31504417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Interleukin-1β Inhibition on Incident Hip and Knee Replacement : Exploratory Analyses From a Randomized, Double-Blind, Placebo-Controlled Trial.
    Schieker M; Conaghan PG; Mindeholm L; Praestgaard J; Solomon DH; Scotti C; Gram H; Thuren T; Roubenoff R; Ridker PM
    Ann Intern Med; 2020 Oct; 173(7):509-515. PubMed ID: 32744862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Thuren T; Zalewski A; Libby P
    Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure.
    Everett BM; Cornel JH; Lainscak M; Anker SD; Abbate A; Thuren T; Libby P; Glynn RJ; Ridker PM
    Circulation; 2019 Mar; 139(10):1289-1299. PubMed ID: 30586730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of Interleukin-1β Blockade With Incident Gout and Serum Uric Acid Levels: Exploratory Analysis of a Randomized Controlled Trial.
    Solomon DH; Glynn RJ; MacFadyen JG; Libby P; Thuren T; Everett BM; Ridker PM
    Ann Intern Med; 2018 Oct; 169(8):535-542. PubMed ID: 30242335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TET2-Driven Clonal Hematopoiesis and Response to Canakinumab: An Exploratory Analysis of the CANTOS Randomized Clinical Trial.
    Svensson EC; Madar A; Campbell CD; He Y; Sultan M; Healey ML; Xu H; D'Aco K; Fernandez A; Wache-Mainier C; Libby P; Ridker PM; Beste MT; Basson CT
    JAMA Cardiol; 2022 May; 7(5):521-528. PubMed ID: 35385050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
    Ridker PM
    Trans Am Clin Climatol Assoc; 2013; 124():174-90. PubMed ID: 23874021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of IL1β by Canakinumab May Be Effective against Diverse Molecular Subtypes of Lung Cancer: An Exploratory Analysis of the CANTOS Trial.
    Wong CC; Baum J; Silvestro A; Beste MT; Bharani-Dharan B; Xu S; Wang YA; Wang X; Prescott MF; Krajkovich L; Dugan M; Ridker PM; Martin AM; Svensson EC
    Cancer Res; 2020 Dec; 80(24):5597-5605. PubMed ID: 33023946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective.
    Zomer E; Liew D; Tonkin A; Trauer JM; Ademi Z
    Int J Cardiol; 2019 Jun; 285():1-5. PubMed ID: 30686493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis.
    Ridker PM
    Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial.
    Ridker PM; Howard CP; Walter V; Everett B; Libby P; Hensen J; Thuren T;
    Circulation; 2012 Dec; 126(23):2739-48. PubMed ID: 23129601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.